Ann Arbor,
Michigan
48109
Purpose:
This study will test a consumer health light therapy device (Re-Timer) for women with
postpartum depression to better understand how it affects mood and the body clock (also
called the circadian clock).
Eligible participants will be enrolled and randomized after baseline assessments. In addition
to using the Re-Timer light for 5 weeks participants will complete questionnaires at various
timepoints, record sleep information, wear an actigraph watch, and provide saliva samples.
Additionally, the sleep of the participants' infants will also be monitored using an
ankle-worn device (actigraph) and sleep diary at certain time-points as this may influence
the mother's mood/sleep, and in turn affect the results.
The hypotheses regarding the bright light versus the placebo dim light of the study are:
- morning bright light therapy will produce greater improvement from pre- to
post-treatment on the Hamilton Rating Scale for Depression
- morning bright light therapy will lengthen the Phase angle difference (PAD) and this
will mediate change in depression symptoms.
- morning bright light therapy will produce greater improvements on self-reported
depression symptoms, excessive daytime sleepiness, maternal-infant bonding, social
functioning, and sleep-related impairment from pre- to post-treatment.
Criteria:
Inclusion Criteria:
- less or equal (≤) to 24 weeks postpartum
- meet criteria for current major depressive disorder per the Structured Clinical
Interview for Diagnostic (SCID) and Statistical Manual of Mental Disorders version 5
(DSM-V)
- not currently receiving treatment for depression (for example, prescription
medications or psychotherapy).
Exclusion Criteria:
- Current diagnosis of Posttraumatic stress disorder (PTSD), obsessive compulsive
disorder, eating disorder, substance abuse or dependence, lifetime history of
mania/hypomania or thought disorder per SCID.
- current diagnosis of, or high risk for, sleep-disordered breathing, insomnia disorder,
restless leg syndrome, and/or narcolepsy.
- retinal pathology or history of eye surgery
- current use of photosensitizing medications,
- current use of exogenous melatonin or medications that may interfere with the
measurement of melatonin (nonsteroidal anti-inflammatory drugs (NSAIDs) if used daily,
and beta-blockers)
- medical conditions for which bright light therapy is contraindicated (for example,
epilepsy/seizures).